Duloxetine as an SNRI treatment for generalized anxiety disorder: Results from a placebo and active-controlled trial

International Clinical Psychopharmacology

Volumn 22, Issue 3, 2007, Pages 167-174

  Hartford, James ^a   Kornstein, Susan ^b   Liebowitz, Michael ^c   Pigott, Teresa ^d   Russell, James ^e   Detke, Michael ^e,f,g   Walker, Daniel ^e   Ball, Susan ^e,f   Dunayevich, Eduardo ^e   Dinkel, Jeff ^e   Erickson, Janelle ^e  

^a Community Research ^*  (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Columbia University School of Medicine ^*  (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anxiolytic; Duloxetine; Generalized anxiety disorder; Placebo; Venlafaxine

Indexed keywords

DULOXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; VENLAFAXINE;

ABNORMAL DREAMING; ADULT; ANALYSIS OF COVARIANCE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FATIGUE; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; INSOMNIA; LIBIDO DISORDER; MALE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; TENSION HEADACHE; XEROSTOMIA; YAWNING;

ADULT; ANXIETY DISORDERS; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE WITHDRAWAL SYNDROME; THIOPHENES; TREATMENT OUTCOME;

EID: 34147165983     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32807fb1b2     Document Type: Article

References (31)

1. Balfour JAB, Jarvis B (2000). Venlafaxine XR extended-release: a review of its clinical potential in the management of generalised anxiety disorder. CNS Drugs 14:483-503.
2. Blier P (2006). Dual serotonin and noradrenaline reuptake inhibitors: focus on their differences. Int J Psychiatry in Clin Practice 10 (Suppl 2):22-32.
3. Dunner DL, Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ (2003). Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety 18:53-61.
4. Goodman WK (2004). Selecting pharmacotherapy for generalized anxiety disorder. J Clin Psychiatry 65 (Suppl 13):8-13.
5. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology, Revised. In: US Department of Health, Education, and Welfare publication (ADM). Rockville, Maryland: National Institute of Mental Health; pp. 76-338.
6. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
7. Hedges LV, Olkin I (1985). Statistical methods for meta-analysis. Orlando: Academic Press, Inc.
8. Kessler RC, Chiu WT, Demler O, Walters EE (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617-627.
9. Koponen H, Allgulander C, Erickson J, Dunayevich E, Pritchett Y, Ball SG, et al. (2007). The efficacy of duloxetine for treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry in press.
10. Liebowitz MR, Gelenberg AJ, Munjack D (2005). Venlafaxine extended release versus placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 62:190-198.
11. Lipsitz J, Kobak K, Feiger A, Sikich D, Moroz G, Engelhardt N (2004). The rater applied performance scale: development and reliability. Psychiatry Res 127:147-155.
12. Malllinckrodt CH, Kaiser CJ, Watkin JG, Molenberghs G, Carroll RJ (2004). The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with the last observation carried forward ANOVA. Clin Trials 1:477-489.
13. Morilak DA, Barrera G, Eschevarria DJ, Garacia AS, Hernandez A (2005). Role of brain norepinephrine in the behavioral response to stress. Prog Neuro-Psychopharmacol Biol Psychiatry 29:1214-1224.
14. Nutt DJ, Ballenger JC, Sheehan D, Wittchen HU (2002). Generalized anxiety disorder: comorbidity, comparative biology, and treatment. Int J Neuropsychopharmacol 5:315-325.
15. Pollack MH (2001). Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission. J Clin Psychiatry 62:20-25.
16. Rickels K, Rynn MA (2001). What is generalized anxiety disorder? J Clin Psychiatry 62:4-11.
17. Rickels K, Pollack MH, Sheehan DV, Haskins JT (2000). Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 157:968-974.
18. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, et al. (2005). Pregabalin for treatment of generalized anxiety disorder. Arch Gen Psychiatry 62:1022-1030.
19. Rodriguez BF, Weisberg RB, Pagano ME, Bruce SE, Spencer MA, Culpepper L, Keller MB (2006). Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients. J Nerv Ment Dis 194:91-97.
20. Rynn MA, Russell JM, Erickson J, Detke M, Ball SG, Dinkel J, et al. (2007). Efficacy and safety of duloxetine in treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety in press.
21. Shear MK, Vander Bilt J, Rucci P, Endicott J, Lydiard B, Otte MW, et al. (2001). Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A). Depress Anxiety 13:166-178.
22. Sheehan DV (1983). The anxiety disease. New York: Charles Scribner and Sons.
23. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. (1998). The MINI International Neuropsychiatric Interview for DSM. J Clin Psychiatry 59 (Suppl 20):34-57.
24. Shelton RC (2004). The dual-action hypothesis: does pharmacology matter? Clin Psychiatry 65 (Suppl 17):5-10.
25. Silverstone PH (2004). Qualitative review of SNRIs in anxiety. J Clin Psychiatry 65 (Suppl 17):19-28.
26. Stahl SM, Grady MM, Moret C, Briley M (2005). SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectrums 10:732-747.
27. Stein DJ, Westenberg HGM, Liebowitz MR (2002). Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry. J Clin Psychiatry 2002:12-19.
28. Tiihonen J, Kuikka J, Rasanen P, Lepola U, Kuponen H, Liuska A, et al. (1997). Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. Mol Psychiatry 2:463-471.
29. Williams VSL, Baldwin DS, Hogue SL, Fehnel SE, Hollis KA, Edin HM (2006). Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey. J Clin Psychiatry 67:204-210.
30. World Medical Association: Declaration of Helsinki: Ethical principles for medical research involving human subjects. World Medical Association. First adopted in 1964; most recent revision in 2000. Available from http://www.wma.net/e/policy/17-c_e.html.
31. Zigmond AS, Snaith RP (1983). The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361-370.